Seres Therapeutics (NASDAQ:MCRB) Sees Unusually-High Trading Volume After Analyst Upgrade

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRBGet Rating) saw an uptick in trading volume on Wednesday after Piper Sandler raised their price target on the stock from $7.00 to $9.00. Piper Sandler currently has an overweight rating on the stock. 55,049 shares changed hands during trading, a decline of 92% from the previous session’s volume of 655,832 shares.The stock last traded at $6.11 and had previously closed at $5.40.

Several other equities research analysts have also recently weighed in on the stock. Chardan Capital reduced their target price on shares of Seres Therapeutics from $16.00 to $12.00 in a research note on Thursday, August 4th. Jefferies Financial Group upgraded shares of Seres Therapeutics to a “buy” rating in a research note on Wednesday, June 8th. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Seres Therapeutics in a research note on Wednesday, June 8th.

Insider Buying and Selling

In other Seres Therapeutics news, major shareholder Health Ltp Fund Ge Nutritional purchased 8,738,243 shares of the company’s stock in a transaction that occurred on Tuesday, July 5th. The stock was purchased at an average price of $3.15 per share, with a total value of $27,525,465.45. Following the completion of the transaction, the insider now directly owns 5,875,711 shares of the company’s stock, valued at approximately $18,508,489.65. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 4.20% of the company’s stock.

Institutional Trading of Seres Therapeutics

Hedge funds have recently modified their holdings of the company. Y Intercept Hong Kong Ltd acquired a new stake in shares of Seres Therapeutics during the second quarter worth approximately $49,000. Centiva Capital LP bought a new position in Seres Therapeutics in the second quarter valued at approximately $50,000. Allspring Global Investments Holdings LLC bought a new position in Seres Therapeutics in the first quarter valued at approximately $52,000. Point72 Hong Kong Ltd bought a new position in Seres Therapeutics in the fourth quarter valued at approximately $63,000. Finally, Lazard Asset Management LLC bought a new position in Seres Therapeutics in the fourth quarter valued at approximately $68,000. Institutional investors and hedge funds own 96.09% of the company’s stock.

Seres Therapeutics Trading Up 17.0 %

The stock has a market capitalization of $784.14 million, a P/E ratio of -5.54 and a beta of 3.03. The company has a debt-to-equity ratio of 2.20, a current ratio of 2.35 and a quick ratio of 2.35. The business’s 50 day simple moving average is $4.60 and its 200-day simple moving average is $5.05.

Seres Therapeutics (NASDAQ:MCRBGet Rating) last announced its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). The business had revenue of $1.22 million during the quarter, compared to the consensus estimate of $6.03 million. Seres Therapeutics had a negative net margin of 75.48% and a negative return on equity of 100.32%. As a group, analysts forecast that Seres Therapeutics, Inc. will post -2.12 EPS for the current year.

Seres Therapeutics Company Profile

(Get Rating)

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).

Read More

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.